Commentary
NAFLD or NASH are nowadays the leading causes of hepatic fibrosis worldwide. In their review, F. Tacke (Charité University Medicine, Berlin, Germany) and R. Weiskirchen (RWTH University Hospital, Aachen, Germany) discuss recent advances in antifibrotic prevention and therapy.
In particular, the authors review the current concepts for antifibrotic drug candidates in the treatment of NAFLD and NASH. Promising results, in particular with the pan-PPAR agonist lanifibranor, support the expectation of an effective pharmacological therapy for liver fibrosis in the near future.
